ImageneBio (IMA) Research & Development (2020 - 2025)
ImageneBio (IMA) posted Research & Development of $15.6 million for Q3 2025, up 286.53% sequentially from $4.0 million in Q2 2025, and up 300.46% YoY from $3.9 million in Q3 2024.
ImageneBio (IMA) Research & Development (2020 - 2025) Analysis & Trends
ImageneBio has reported Research & Development for 6 years, with the latest figure at $15.6 million in Q3 2025.
- Quarterly Research & Development rose 300.46% year-over-year to $15.6 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $26.1 million (down 37.73% YoY) and the FY2024 annual result came in at $30.9 million, down 48.24% from the prior year.
- Research & Development advanced to $15.6 million in Q3 2025 per IMA's latest filing, from $4.0 million in the prior quarter.
- Over five years, Research & Development peaked at $18.8 million in Q3 2022 and troughed at $2.5 million in Q4 2024.
- A 5-year average of $11.8 million and a median of $14.0 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2024 and 2025: Research & Development plunged 82.31% in 2024, then soared 300.46% in 2025.
- Over 5 years, Research & Development stood at $12.3 million in 2021, then grew by 26.75% to $15.6 million in 2022, then decreased by 8.73% to $14.3 million in 2023, then sank by 82.31% to $2.5 million in 2024, then surged by 516.16% to $15.6 million in 2025.
- According to Business Quant data, Research & Development over the past three periods registered $15.6 million, $4.0 million, and $4.0 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | ImageneBio | 48.60 Mn | -86.75 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 15.56 Mn |
| Jun 30, 2025 | 4.03 Mn |
| Mar 31, 2025 | 4.04 Mn |
| Dec 31, 2024 | 2.53 Mn |
| Sep 30, 2024 | 3.89 Mn |
| Jun 30, 2024 | 9.83 Mn |
| Mar 31, 2024 | 14.00 Mn |
| Dec 31, 2023 | 14.27 Mn |
| Sep 30, 2023 | 14.65 Mn |
| Jun 30, 2023 | 15.17 Mn |
| Mar 31, 2023 | 15.55 Mn |
| Dec 31, 2022 | 15.64 Mn |
| Sep 30, 2022 | 18.85 Mn |
| Jun 30, 2022 | 15.49 Mn |
| Mar 31, 2022 | 14.34 Mn |
| Dec 31, 2021 | 12.34 Mn |
| Sep 30, 2021 | 13.38 Mn |
| Jun 30, 2021 | 11.37 Mn |
| Mar 31, 2021 | 10.02 Mn |
| Dec 31, 2020 | 23.40 Mn |